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increasingly clear that even accurate measurements of retinal thickness may fail to predict visual
outcomes for many diseases. As a result, the focus of much current clinical imaging research is
on the identiﬁcation of other OCT-derived anatomic biomarkers predictive of visual outcomes –
such biomarkers could serve as surrogate endpoints in clinical trials and provide prognostic infor-
mation in clinical practice. In this review, we begin by highlighting the importance of accurate visual
function assessment and describing the fundamentals of OCT image evaluation, before describing
the current state-of-the-art with regard to predicting visual outcomes, for a variety of macular dis-
eases, using OCT.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
2. Visual function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1472.1. Visual acuity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
2.2. Reading speed and contrast sensitivity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
2.3. Microperimetry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1483. Optical coherence tomography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.1. Qualitative analysis of OCT images in ‘‘Normal’’ eyes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.2. Quantitative OCT image analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1484. Neovascular age-related macular degeneration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4.1. Neurosensory retina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
4.2. Pigment epithelium detachment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.3. Subretinal hyperreﬂective material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.4. Subretinal ﬂuid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.5. Vitreomacular interface abnormalities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1505. Retinal vascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1515.1. Diabetic maculopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
5.2. Retinal vein occlusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
5.3. Uveitic syndromes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1526. Central serous chorioretinopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
7. Non-neovascular age-related macular degeneration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
8. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1531. Introduction
The advent of fundus ﬂuorescein angiography in the 1960s her-
alded a revolution in our understanding of macular diseases,
with the insights afforded by such imaging providing the basis
for the development and application of many new therapeutic
approaches (Keane and Sadda, 2010). At the same time, ad-
vances in color photography led to the acquisition of fundus
images with enhanced resolution, stereopsis, and ﬁeld of view,
allowing medical retina specialists to segregate the retinal from
the choroidal circulations and to isolate anatomic compart-
ments within the fundus (Yannuzzi et al., 2004). Thus, ﬂuores-
cein angiography and stereoscopic color fundus photography
came to form the fundamental basis for the care of patients with
macular disease andwere quickly incorporated into related clin-
ical trials. In these trials, photographic and angiographic de-
rived parameters were adopted as anatomic endpoints, with
the information providing helping to optimize many new ther-
apeutic approaches (Fine, 2005). For example, in the EarlyTreatment Diabetic Retinopathy Study (ETDRS) color pho-
tography was used to deﬁne a subset of patients with diabetic
maculopathy who were likely to beneﬁt from laser photocoagu-
lation (Early Treatment Diabetic Retinopathy Study Research
Group, 1985); and in the Macular Photocoagulation Study
(MPS) the importance of recognizing ‘‘classic’’ and ‘‘occult’’
patterns of ﬂuorescein leakage was identiﬁed in patients receiv-
ing treatment for neovascular age-related macular degeneration
(AMD) (Macular Photocoagulation Study Group, 1996).
More recently, evaluation of macular disease has under-
gone a further revolution, with the introduction of a wholly
new imaging modality – optical coherence tomography
(OCT) (Keane and Sadda, 2008). OCT is analogous to ultraso-
nography, but utilizes light waves instead of sound waves, thus
providing cross-sectional images of the retina with unprece-
dented detail and resolution, and in a non-invasive manner
(Drexler and Fujimoto, 2008; Schuman et al., 2004). The appli-
cation of this imaging modality by medical retina specialists
has clariﬁed many aspects of chorioretinal disease pathophys-
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characteristics (Keane and Sadda, 2010). From an early stage
in its development, OCT has also been revolutionary in
attempting to extract clinically useful measurements from im-
age data in an automated fashion (Hee et al., 1995a,b). As a
result, OCT-derived measurements of retinal thickness have
been rapidly embraced in clinical and research settings (Hee
et al., 1998; Brown and Regillo, 2007; Keane et al., 2009a;
Keane and Sadda, 2009).
In clinical imaging research, much of the focus has been on
the identiﬁcation of novel OCT-derived anatomic biomarkers
for use in clinical trials and subsequently in clinical practice
(Ahlers et al., 2008a,b; Keane et al., 2008a,b; Kiss et al.,
2009). In clinical trials, such biomarkers may provide valuable
information regarding therapeutic mechanisms of action,
pharmacodynamics, and pharmacokinetics (Keane et al.,
2008b). They may be of most value, however, when they can
serve as surrogate endpoints – endpoints that are reasonably
likely, based on epidemiologic, therapeutic, pathophysiologic,
or other evidence, to predict clinical beneﬁt (Csaky et al.,
2008; Duivenvoorden et al., 2009). If, and when, these criteria
are fulﬁlled, OCT-derived morphologic parameters could be
employed to increase the accuracy, reduce the costs, and
potentially shorten the duration of clinical trials (Csaky
et al., 2008; Lloyd et al., 2008). Similarly, in clinical practice,
such parameters could extend the application of OCT imaging
beyond simple diagnosis and toward prognosis. With the rapid
evolution of new treatments for macular disease (Zarbin and
Rosenfeld, 2010), such prognostic information may be crucial
for the clinician in choosing the appropriate type and level of
treatment, as well as for appropriate counseling of patients.
Therefore, the importance of predicting visual outcomes for
macular disease using OCT imaging is clear. Unfortunately
however, many studies using OCT-derived measurements of
retinal thickness have failed to ﬁnd consistent correlations with
visual outcomes (Moutray et al., 2008; Spaide et al., 2006).
These failures may be related, at least in part, to the signiﬁcant
errors that are known to occur in automated retinal thickness
measurements for many macular diseases (Sadda et al., 2006;
Keane et al., 2009b). As our knowledge of OCT image analysis
has grown, however, it has become progressively clear that
even accurate measurements of retinal thickness may fail to
predict visual outcomes, and that further progress may be
dependent on the discovery of other, more novel, OCT-derived
morphologic parameters (Keane et al., 2008a). It is also
increasingly clear that prediction of visual outcomes will be
dependent on accurate assessment of visual function – an area
where signiﬁcant advances have also been made (Keane et al.,
2010a).
In this review, we begin by highlighting the importance of
accurate visual function assessment and describing the funda-
mentals of OCT image evaluation, before describing the current
state-of-the-art with regard to predicting visual outcomes, for a
variety of macular diseases, using OCT imaging.2. Visual function
2.1. Visual acuity
Visual acuity is a measure of the spatial resolving ability of the
visual system under conditions of high contrast (Neelam et al.,2009). Both in clinical practice and in clinical research, dis-
tance visual acuity is the most frequently used test of visual
function (Holladay, 2004). In clinical practice, distance visual
acuity is most commonly assessed using Snellen optotype test
charts, ﬁrst introduced by Herbert Snellen in 1862 (an opto-
type is a standardized symbol for testing vision and can be a
specially shaped letter, number, or geometric symbol). Snellen
visual acuities express the angular size of an optotype as a frac-
tion, with the numerator specifying the test distance, and the
denominator specifying the line read. However, the limitations
of Snellen test charts are well established, and include an un-
equal legibility of letters, unequal spacing between letters and
rows, and an unequal progression of difﬁculty between lines
(Neelam et al., 2009; Hogg and Chakravarthy, 2006). These
ﬂaws result in many clinical problems, such as inaccurate mea-
surement of visual acuity in children with amblyopia as a result
of crowding phenomena, and limited assessment of visual acu-
ity in patients with low vision in disorders such as advanced
AMD (Falkenstein et al., 2007). Furthermore, the test–retest
variability using Snellen charts has proven low, and many sta-
tistical analyses are not possible using visual acuities expressed
as Snellen fractions (Lovie-Kitchin, 1988).
The limitations of Snellen visual acuity charts led to the
development of ‘‘logMAR’’ (logarithm of the minimum angle
of resolution) charts by Bailey and Lovie (1976). The major
advantages of these charts include the regular geometric pro-
gression of letter size and spacing (following a logarithmic
scale in steps of 0.1 log units), the equal number of letters in
each row (ﬁve), and the comparable legibility of the ﬁve Sloan
optotypes used. As a result, the logMAR charts used for the
ETDRS study have emerged as the test-of-choice for measur-
ing distance visual acuity in vision research. Despite their supe-
riority, logMAR charts have not replaced Snellen charts in
clinical practice. It is perhaps not surprising, then, that many
retrospective clinical studies have failed to predict visual out-
comes using OCT-derived parameters (Moutray et al., 2008).
2.2. Reading speed and contrast sensitivity
Distance visual acuity is largely a function of foveal integrity,
i.e. it measures the central 1–2 of visual ﬁeld (although
extrafoveal ﬁxation may sometimes occur in patients with mac-
ular disease) (Moutray et al., 2008). Therefore, the assessment
of other visual parameters, such as contrast sensitivity and
reading speed, may better reﬂect macular integrity as a whole,
and thus provide stronger correlations with OCT-derived mor-
phologic parameters (Keane et al., 2010a).
As distance visual acuity is measured in conditions of high
contrast, some patients with macular disease may have near-
normal distance visual acuity measurements, yet have signiﬁ-
cantly decreased contrast sensitivities (Arditi, 2005; Mone´s
and Rubin, 2005; Patel et al., 2009a). This distinction is of
functional importance – contrast sensitivity has been closely
linked with both orientation and mobility and thus may pro-
vide valuable additional information regarding functional sta-
tus in patients with macular disease (Arditi, 2005). In most
clinical trials, contrast sensitivity is measured using Pelli-Rob-
inson charts and such measurements have been also found to
be highly predictive of reading performance (Neelam et al.,
2009). Word reading is a complex process that requires a vari-
ety of component processes, such as letter and word resolution,
stability of retinal images, saccadic accuracy, and accurate
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cannot be determined accurately in illiterate patients, and is of-
ten impaired due to non-visual factors (Elliott et al., 2001), it is
minimally affected by media opacities such as cataract (Elliott
et al., 2000), and is strongly associated with vision-related
quality of life (Hazel et al., 2000). Thus, as new treatments con-
tinue to emerge for previously intractable macular disorders,
assessment of both contrast sensitivity and reading ability
may attain a position of increased importance for medical ret-
ina specialists in clinical settings and as a secondary endpoint
in clinical trials (Csaky et al., 2008).
2.3. Microperimetry
While distance visual acuity is the most widely used measure of
visual function in macular disease, an alternative approach is
to measure paracentral retinal sensitivity using perimetry
(Rohrschneider et al., 2008). So-called ‘‘microperimetry’’ al-
lows direct, real-time evaluation of retinal ﬁxation and macu-
lar sensitivity, and thus accurate comparison of fundus
characteristics versus function in macular disease (Midena
et al., 2007, 2010). Currently, the most commonly used mic-
roperimeter is the MP1 microperimeter (Nidek Technology,
Gamagori, Japan) – this device allows the examiner to conduct
automated static perimetry, while the use of a built-in infrared
camera allows the instrument to track the patient’s eye move-
ments and present the stimuli at exact, predeﬁned, retinal foci
(Midena et al., 2010; Weingessel et al., 2009). Recent studies
have overlaid microperimetric sensitivity maps with dense
OCT raster scan datasets through the registration of color fun-
dus photographs obtained with both devices – such an ap-
proach has allowed a systematic correlation between OCT-
derived morphologic parameters and functional alterations in
disorders such as diabetic maculopathy (Dea´k et al., 2010b).
In addition, microperimetry is increasingly being incorporated
into clinical trials, however, advances in image registration, eye
tracker technology, and testing strategies, are still required to
reduce the test–retest variability of these devices (Chen et al.,
2009).3. Optical coherence tomography
OCT, ﬁrst described by Huang et al. (1991), allows high-
resolution tomographic (cross-sectional) images of the neuro-
sensory retina to be obtained in a non-invasive manner (Keane
and Sadda, 2008). Commercially available OCT systems are
now capable of obtaining retinal images with an axial resolu-
tion of approximately 3–8 lm, and a transverse resolution of
approximately 14–20 lm (Kiernan et al., 2010).
3.1. Qualitative analysis of OCT images in ‘‘Normal’’ eyes
Light waves traveling through tissue can be reﬂected, scattered,
or absorbed at each tissue interface – as a result, the multi-
layered structure of the retina is particularly amenable to
assessment using OCT (Schuman et al., 2004). However, care
must be taken when making assumptions about the correlation
between OCT images and retinal histological sections – the
strength of backscattered light is related to its angle of inci-
dence on the area of interest. Therefore, structures running ob-
liquely in the retina, such as Henle ﬁber layer, are often notwell visualized on standard OCT images (Lujan et al., 2010;
Otani et al., 2010).
On OCT false-color B-scans, highly reﬂective tissue is red-
dish-white in color, while hyporeﬂective tissue is blue-black
in color (Schuman et al., 2004; Brar et al., 2009b). On most
OCT scans, the ﬁrst hyperreﬂective layer detected is the inter-
nal limiting membrane (ILM) at the vitreoretinal interface. In
a subset of the population, the posterior hyaloid may be seen
as a thin hyperreﬂective layer above the ILM. Within the ret-
ina, the ganglion cell layer and both the inner and outer plex-
iform layers are seen as hyperreﬂective layers while the inner
and outer nuclear layers are hyporeﬂective. Recent studies
have also shown that, by varying the measurement beam,
two aspects of the outer plexiform layer may be alternately
seen: (1) a thin hyperreﬂective layer corresponding to the pho-
toreceptor synapses, and (2) a thicker hyperreﬂective layer cor-
responding to photoreceptor axonal extensions (Henle ﬁber
layer) enveloped by the outer cytoplasm of Muller cells (Lujan
et al., 2010; Otani et al., 2010).
Correlation of OCT images with the microstructure of the
outer retina is less well deﬁned than that of the inner retina
(Srinivasan et al., 2008; Gloesmann et al., 2003). The ﬁrst con-
tinuous hyperreﬂective line typically seen in the outer retina is
believed to correspond to the junction of the inner and outer
segments of the photoreceptors (IS–OS junction). A faint, less
continuous hyperreﬂective line may be present above this line
and is thought to represent the external limiting membrane
(ELM). Beneath the IS–OS junction, the interdigitations of
the photoreceptor outer segments and apical microvilli of the
RPE may be visible with high-resolution OCT systems. Final-
ly, a wide, hyperreﬂective line corresponding to the RPE–
Bruch membrane–choriocapillaris complex lies at the outer-
most extent of these tissue layers. With newer OCT devices,
using speciﬁc scanning protocols, visualization of choroidal
structure, and the choroidal–scleral junction, is also possible
(Spaide et al., 2008).3.2. Quantitative OCT image analysis
The high axial resolution offered by OCT is well suited to the
objective, accurate measurement of retinal thickness (Hee
et al., 1995b). Stratus OCT (Carl Zeiss Meditec, Dublin,
CA), the ﬁrst widely adopted commercial OCT system, uses
image processing techniques to automatically detect the inner
and outer retinal boundaries on OCT B-scans (segmentation)
and thus provides measurements of retinal thickness (Schuman
et al., 2004). Using these techniques, it is possible to measure
retinal thickness at multiple locations and to construct retinal
thickness maps corresponding to the ETDRS subﬁelds (Hee
et al., 1998). Caution is required, however, as errors in auto-
mated measurements are known to occur, and these errors
are often severe in macular disorders with complex morphol-
ogy such as neovascular AMD (Sadda et al., 2006; Patel
et al., 2009b). Newer OCT systems offer considerably im-
proved image acquisition speed, as well as improved sensitivity
and axial resolution. These changes have facilitated improved
accuracy in retinal segmentation; however, further improve-
ments in image processing algorithms are still required before
segmentation errors can be eliminated entirely, particularly for
disorders such as neovascular AMD (Keane et al., 2009b;
Krebs et al., 2009).
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AMD is the leading cause of irreversible visual loss in elderly
populations in the developed world, the majority of which is
attributable to the neovascular form of this disorder (Klein
et al., 2011). Currently, severe visual loss can be prevented in
most patients with neovascular AMD through the use of
anti-angiogenic agents such as ranibizumab or bevacizumab
(Lucentis and Avastin, respectively, Genentech, South San
Francisco, CA) (Tufail et al., 2010; Rosenfeld et al., 2006;
Brown et al., 2006). However, these therapies typically only re-
sult in signiﬁcant visual improvement for about one-third of
those treated. Furthermore, at presentation many patients
have advanced disease that ultimately proves refractory to
therapy (Rosenfeld et al., 2010). Anti-angiogenic therapy is
also costly and requires frequent intraocular injections over ex-
tended time periods (Smiddy, 2009). Prediction of visual out-
comes from OCT images, and identiﬁcation of those patients
likely to respond to these and other treatments, thus represents
a signiﬁcant and unmet clinical need.
The complex morphology of neovascular AMD presents a
number of unique challenges for the prediction of visual out-
comes from OCT. In neovascular AMD, abnormal blood ves-
sels develop from the choroidal circulation, pass anteriorly, and
proliferate in the subretinal pigment epithelium (RPE) or sub-
retinal space (Grossniklaus and Green, 2004). The resulting
hemorrhage, ﬂuid exudation, and ultimately ﬁbrosis, of these
vessels typically results in severe visual loss, particularly if left
untreated. The prototypical feature of neovascular AMD –
choroidal neovascularization (CNV) – thus results in a wide
range of alterations in chorioretinal morphology, with intraret-
inal, subretinal, and sub-RPE components of differing sizes and
locations relative to the fovea. CNV occurs in many disorders
other than neovascular AMD, albeit less commonly (e.g. path-
ologic myopia, trauma, and miscellaneous ocular inﬂammatory
disorders) (Grossniklaus and Green, 2004). While some varia-
tion is likely, the insights provided by the characterization of
neovascular AMD using OCT may also be useful for the man-
agement of patients with CNV of other etiologies.4.1. Neurosensory retina
Invasion and proliferation of the CNV lesion results in signif-
icant degradation and remodeling of the retinal extracellular
space, as well as the incursion of cellular components such as
ﬁbroblasts (Grossniklaus and Green, 2004). The resultant dis-
ruption of the ELM–photoreceptor complex in the outer retina
often leads to accumulation of ﬂuid in the neurosensory retina
(Gass, 1997). Thus, thickening of the neurosensory retina is a
common feature in patients with neovascular AMD (Keane
et al., 2008b, 2009c). Despite this, many studies have failed
to ﬁnd a signiﬁcant correlation between increases in retinal
thickness and decreases in visual function (Moutray et al.,
2008; Spaide et al., 2006). This failure may be related, at least
in part, to the frequency inaccuracy of automated retinal
boundary segmentation in patients with neovascular AMD
(Keane et al., 2009a; Patel et al., 2009b). In an effort to reduce
these errors, manual segmentation of OCT images can be per-
formed; studies using this approach have successfully demon-
strated signiﬁcant correlations between retinal thickness and
visual function (Keane et al., 2008a, 2009c). In subjectsenrolled in the Avastin (Bevacizumab) for Choroidal Neovas-
cularization (ABC) Trial, prior to treatment, increased retinal
thickness at the foveal center was signiﬁcantly associated with
decreased visual function – approximately 20% of the varia-
tion in ETDRS visual acuity seen in these patients could be ex-
plained by thickening of the neurosensory retina (Keane et al.,
2010a).
Many studies have also failed to detect a signiﬁcant corre-
lation between reductions in retinal thickness as a result of
treatment and associated improvements in visual acuity (Spa-
ide et al., 2006). However, there is evidence, from the PrONTO
study, to suggest that reduction in retinal thickness at 1 month
following initiation of ranibizumab therapy may show a mod-
est correlation with longer-term visual outcomes (i.e. visual
acuity at 12 and 24 months post-treatment initiation) (Fung
et al., 2007; Lalwani et al., 2009). Stronger longitudinal corre-
lations have again been found using manual segmentation of
OCT images; one such study, while failing to detect associa-
tions between reduced retinal thickness and improved visual
acuity, has demonstrated that ‘‘regression’’ of initial anatomic
improvements over time may be associated with longer-term
visual loss (Keane et al., 2009c). Such ﬁndings may have impli-
cations for OCT-derived dosing regimens where increased
intraretinal ﬂuid acts as a trigger for retreatment – the ﬂuctu-
ations in retinal thickness that can occur in such regimes may
have an adverse effect on the ultimate visual outcome (Mitchell
et al., 2010).
Failure to detect a stronger correlation between thickness of
the neurosensory retina and visual outcomes may be related to
the heterogeneous structural characteristics of this disorder –
retinal thickening is often less marked in lesions where CNV
growth is contained entirely beneath the RPE (type 1 CNV)
(Keane et al., 2008a; Liakopoulos et al., 2008). Moreover, cho-
roidal neovascular exudation may result in varying patterns of
intraretinal ﬂuid collection on OCT. Initially, intraretinal ﬂuid
may be seen as diffuse retinal thickening beginning in the outer
nuclear and outer plexiform layers; subsequently, with more
severe exudation, cystoid spaces may form. These spaces
may be seen on OCT as round or oval hyporeﬂective areas,
with larger spaces often containing tissue septa and involving
all layers of the retina (Ting et al., 2002). In disorders such
as diabetic maculopathy (see later), the presence of cystoid
macular edema (CME) is often associated with more severely
reduced visual acuity than diffuse retinal thickening alone
(Keane and Sadda, 2009). In addition, it has been suggested
that, in neovascular AMD, the presence of cystoid changes
may mask the presence of retinal neuronal cell loss (Kashani
et al., 2009). To account for these possibilities, quantiﬁcation
of cystoid spaces is possible using manual segmentation of
OCT images. However, using this approach, Kashani et al.
failed to detect a signiﬁcant relationship between cystoid space
volume and visual acuity and failed to improve the strength of
retinal thickness–visual acuity correlation through adjustment
for intraretinal cystoid space thickness (Kashani et al., 2009).
A number of other features associated with intraretinal
ﬂuid exudation have been described in patients with neovascu-
lar AMD. In some patients with chronic exudation, irreparable
structural changes may occur and, as a result, cystoid spaces
may persist even in the absence of leakage; such changes are
often described as ‘‘cystoid macular degeneration’’ (Iida
et al., 2003). Furthermore, when monitoring patients following
treatment for neovascular AMD, the recurrence of intraretinal
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tion’’ – a recently described OCT ﬁnding (Zweifel et al., 2009).
Outer retinal tubulations are branching tubular structures that
appear as round or ovoid hyporeﬂective spaces with hyperre-
ﬂective borders in the outer nuclear layer (commonly overlying
areas of pigment epithelium detachment (PED) or subretinal
ﬁbrosis). They are most commonly seen in patients with neo-
vascular AMD, but may also be seen in other disorders. Outer
retinal tubulations may represent a rearrangement of photore-
ceptors in response to injury – their association with visual
outcomes has yet to be examined.
Failure to detect a strong correlation between thickness of
the neurosensory retina, and visual outcomes, may also be re-
lated to the disease state at examination – more advanced le-
sions may be associated with substantial photoreceptor
degeneration, thus complicating any analyses (Kim et al.,
2002a). Furthermore, in some patients, geographic atrophy
(GA) – and thus reduced retinal thickness – may predate the
occurrence of CNV (Kim et al., 2002b; Sunness, 1999, 2006).
In an attempt to address this, Kashani et al. evaluated the rela-
tionship between visual acuity and the thickness and volume of
the outer nuclear layer in patients with neovascular AMD
(Kashani et al., 2009). In this study, outer nuclear layer volume
was correlated with visual acuity, although the strength of the
association remained modest. Photoreceptor degeneration is
also believed to be visible on OCT images as disruption of
the thin hyperreﬂective lines in the outer retina that are
thought to represent the ELM and photoreceptor IS–OS junc-
tions (Hayashi et al., 2009; Oishi et al., 2010; Sayanagi et al.,
2009). In patients with neovascular AMD, the ELM and IS–
OS junction are often seen to be intact on OCT images in those
patients who have responded well to therapy – the role of these
parameters as prognostic indicators in neovascular AMD re-
mains less clear.
4.2. Pigment epithelium detachment
Growth of the choroidal neovascular membrane in the sub-
RPE space produces an elevated lesion visible on clinical
examination, termed a ﬁbrovascular PED; this growth is often
accompanied by variable amounts of ﬂuid leakage or frank
hemorrhage (when either of these predominate the lesion is of-
ten described as a serous or hemorrhagic PED) (Macular Pho-
tocoagulation Study Group, 1991). On OCT examination,
PEDs appear as broad elevations of the RPE band relative
to Bruch membrane (Coscas et al., 2007). Using quantitative
subanalysis, it is possible to quantify the thickness and volume
of PEDs in patients with neovascular AMD (Joeres et al.,
2007a,b). However, to date, no consistent correlation has been
found between PED measurements and visual function (Keane
et al., 2008a, 2010a). This lack of correlation is perhaps not
surprising as the presence of CNV beneath the RPE may not
always result in disruption of photoreceptor–RPE interactions
(it is also in line with experience from clinical practice, where it
is relatively common to see large ﬁbrovascular PEDs that
prove refractory to treatment but where adequate visual func-
tion is maintained) (Gass, 1997). The failure to ﬁnd a signiﬁ-
cant correlation may also be related to the relative inability
of conventional OCT devices to visualize the areas underneath
the highly reﬂective RPE and thus to characterize PED sub-
types. Recent studies have utilized ‘‘enhanced depth’’ spectral
domain OCT imaging to aid visualization of the sub-RPEspace and have shown that many ﬁbrovascular PEDs appear
to be ﬁlled with solid layers of material of medium reﬂectivity,
separated by hyporeﬂective clefts (Spaide et al., 2008; Spaide,
2009). Prototype OCT devices utilizing longer wavelength light
sources to aid light penetration have also allowed improved
visualization of choroidal structure (Yasuno et al., 2009). Fur-
ther studies will be required to accurately characterize OCT-
derived images of choroidal structure and subsequently to
determine their prognostic signiﬁcance, if any.
4.3. Subretinal hyperreﬂective material
In many cases of neovascular AMD, vessels from the choroidal
neovascular complex may pass directly into the subretinal
space after their initial penetration of Bruch membrane
(Grossniklaus and Green, 2004; Green and Enger, 1993; Green
et al., 1985). In these initial growth phases, the CNV mem-
brane is often highly vascular and appears on OCT as an
amorphous lesion of medium- to high-reﬂectivity above the
RPE (Liakopoulos et al., 2008; Joeres et al., 2007b). As the
CNV lesion becomes less active over time, the vascular compo-
nent typically regresses, while the ﬁbrous component increases,
resulting in disciform scar formation that appears on OCT as a
well demarcated highly hyperreﬂective lesion. A number of
studies have demonstrated that the total volume of subretinal
tissue present correlates with visual parameters such as dis-
tance acuity, reading ability, and contrast sensitivity (Keane
et al., 2008a, 2010a; Kashani et al., 2009). For example, in
the ABC trial, approximately 24% of the variation in contrast
sensitivity at the baseline could be accounted for by increases
in the total volume of subretinal tissue (Keane et al., 2010a).
Since the positioning of the ﬁbrovascular tissue in the subreti-
nal space may disrupt communication between the photore-
ceptors and the RPE, a deleterious effect on contrast
sensitivity is not surprising (Gass, 1997).
4.4. Subretinal ﬂuid
As the choroidal neovascular membrane grows, it is often
accompanied by profuse leakage from its immature blood ves-
sels (Grossniklaus and Green, 2004). Consequently, pockets of
ﬂuid commonly accumulate between the neurosensory retina
and the RPE, and these areas may be seen on OCT as hypore-
ﬂective spaces (Joeres et al., 2007b). When ﬂuid exudation is
serous in nature, subretinal ﬂuid pockets are seen on OCT as
homogenous hyporeﬂective spaces; when the exudate contains
ﬁbrin or red blood cells, the area of subretinal ﬂuid may by
sparsely hyperreﬂective (Keane et al., 2010b). Spectral domain
OCT allows enhanced visualization of the subretinal space and
assessment of the optical density of subretinal ﬂuid compart-
ments may have value for the differentiation of macular disor-
ders associated with subretinal accumulation (Ahlers et al.,
2009b). Weak correlations have been reported between in-
creased volumes of subretinal ﬂuid and decreased contrast sen-
sitivity, although evidence for its association with other visual
parameters in neovascular AMD is lacking (Keane et al.,
2010a).
4.5. Vitreomacular interface abnormalities
Retinal imaging with OCT allows detailed evaluation of the
vitreomacular interface (Mirza et al., 2007). On OCT,
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posterior hyaloid causes deformation of the inner retinal sur-
face, which may often be accompanied by CME (Koizumi
et al., 2008). Epiretinal membranes (ERMs) are often seen
on OCT as hyperreﬂective bands anterior to the inner retinal
surface, with distortion of the underlying anatomy (Legarreta
et al., 2008). A number of authors have recently suggested that
vitreomacular interface abnormalities may play a role in the
pathogenesis of CNV (Lee et al., 2009; Mojana et al., 2008;
Krebs et al., 2007; Nomura et al., 2010; Robison et al.,
2009). Further study is required to conﬁrm this theory and
to determine whether it has any prognostic implications.5. Retinal vascular disease
Although histopathologic reports suggest that the features of
retinal vascular disease may vary according to its underlying
etiology (e.g. intraretinal cyst location and extent; serous reti-
nal detachment frequency and severity) (Traustason et al.,
2009; Fine and Brucker, 1981), the lessons learnt from charac-
terization of diabetic maculopathy using OCT may also be
important for the management of other diseases where the
tomographic features have been less well-deﬁned (Keane and
Sadda, 2009).
5.1. Diabetic maculopathy
On OCT, diabetic macular edema (DME) is generally seen as
an area of retinal thickening that is often accompanied by loss
of the foveal depression. Approximately 90% of patients with
DME show evidence of sponge-like retinal thickening associ-
ated with decreased optical backscattering on OCT – this
thickening may be localized to the outer nuclear layer, or ex-
tend diffusely to involve the entire retina (Kim et al., 2009;
Otani et al., 1999). Sponge-like retinal thickening is often seen
in association with both CME and serous retinal detachment,
however, it may also occur in isolation, particularly in patients
with mild-moderate nonproliferative diabetic retinopathy, and
in this context is associated with less severe visual loss
(Alkuraya et al., 2005). Approximately 50% of patients with
DME demonstrate evidence of round or oval hyporeﬂective
areas on OCT consistent with intraretinal cystoid spaces
(Otani et al., 1999; Kim et al., 2006). On FA, leakage into
cystoid spaces may result in a ‘‘petalloid’’ or ‘‘honeycomb’’
appearance. On OCT, petalloid hyperﬂuorescence is associated
with cystoid space formation in the radially arranged outer
plexiform layer of Henle, while honeycomb hyperﬂuorescence
correlates with cystoid space in the vertically arranged inner
nuclear layer (Otani and Kishi, 2007). Detection of CME on
OCT is associated with a more severe reduction in visual acuity
and a poorer response to treatment than OCTs displaying
sponge-like retinal thickening alone (Brasil et al., 2007). Using
microperimetry, Dea´k et al. have demonstrated that outer
nuclear layer cysts – in particular those >220 lm in size – have
greater negative effects on retinal sensitivity than inner nuclear
layer cysts (Dea´k et al., 2010b).
Approximately 15–30% of patients with DME demonstrate
evidence of serous retinal detachment on OCT (Catier et al.,
2005; Ozdemir et al., 2005a,b; Gaucher et al., 2008). Serous
retinal detachment occurs when ﬂuid accumulation leads to
separation of the neurosensory retina and the RPE, and is seenon OCT as a hyporeﬂective space. The presence of a serous ret-
inal detachment may represent a speciﬁc feature of a severe
stage of DME (Kim et al., 2006; Alkuraya et al., 2009),
although this feature may occur even when the central retinal
thickness above the detachment is within the normal range
(Gaucher et al., 2008). Furthermore, serous retinal detachment
may resolve despite worsening of DME, and the presence of
this feature on OCT does not appear indicative of a poor prog-
nosis (Gaucher et al., 2008; Ozdemir et al., 2005b).
In areas of long-standing edema, lipid and protein may pre-
cipitate in the outer retina, forming hard exudates that appear
as focal areas of hyperreﬂectivity with posterior shadowing
(Otani and Kishi, 2001; Bolz et al., 2009). In some cases these
foci can be located on OCT before they can be seen on either
biomicroscopy, color photography, or infrared imaging and
may thus constitute a marker for early subclinical blood–
retinal-barrier breakdown in DME (Bolz et al., 2009). In more
advanced cases, these foci may become conﬂuent forming
hyperreﬂective plaques in the outer plexiform and outer
nuclear layers and resulting in decreased retinal sensitivity
(Dea´k et al., 2010a,b; Ota et al., 2010a).
Abnormalities of the vitreomacular interface are also com-
monly seen in DME (Gaucher et al., 2005; Ghazi et al., 2007).
On OCT, the posterior hyaloid may be seen as a thin hyperre-
ﬂective membrane with a broad or focal adhesion to the retinal
surface. In patients with DME, this membrane often appears
thickened and taut, exerting obvious traction on the retina
and resulting in a characteristic peaked appearance. ERMs
also commonly form in patients with DME and may be clearly
seen on OCT. Identiﬁcation of these features is important as
surgical intervention may lead to signiﬁcantly improved visual
outcomes (Otani and Kishi, 2000; Patel et al., 2006; Thomas
et al., 2005). Thus, evaluation of the vitreomacular interface
should always be performed in patients with DME, particu-
larly when retinal thickening is present on clinical examination
but ﬂuorescein angiography discloses no signiﬁcant leakage or
ischemia.
Ischemic changes are commonly seen in patients with dia-
betic maculopathy and may have a negative impact on visual
function, as well as on response to treatment, in patients with
DME (in a minority of patients, visually signiﬁcant ischemic
maculopathy may also occur in the absence of DME)
(Bresnick et al., 1984; Conrath et al., 2005). In general, the
features and natural history of diabetic ischemic maculopathy
remain poorly understood – a ﬁnding reﬂected in the relative
paucity of related OCT studies. Recently however, studies
using spectral domain OCT have shown that macular ischemia
is associated with disorganization and loss of inner retinal
layers, as well as reductions in retinal sensitivity (Yeung
et al., 2009; Byeon et al., 2009). Other evidence suggests that
eyes with cystoid spaces at the foveal center on OCT may have
larger foveal avascular zones on ﬂuorescein angiography
(Murakami et al., 2010). As anti-angiogenic therapies are
introduced for the treatment of DME, further research is
necessary to more completely characterize the OCT features
of diabetic macular ischemia and thus determine their
prognostic signiﬁcance.
Numerous studies have used a quantitative approach when
examining the correlation between visual acuity and OCT-
derived features in patients with DME (Hee et al., 1995b,
1998; Otani et al., 1999; Catier et al., 2005; Goebel and
Kretzchmar-Gross, 2002; Massin et al., 2003). Initial studies
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nal thickness and decreased visual acuity, although many
involved small sample sizes and lacked best-corrected ETDRS
visual acuities. The evidence from more recent studies is less
clear, with the most comprehensive data to date suggesting a
modest correlation between OCT-measured foveal center point
thickness and visual acuity (r= 0.52), and a modest correla-
tion between changes in retinal thickening and visual acuity
after laser treatment for DME (r= 0.44) (Network et al.,
2007). The strength of the observed correlations may be
treatment-dependent – in a recent randomized controlled trial
assessing the efﬁcacy of intravitreal triamcinolone, no statisti-
cally signiﬁcant correlation was detected between changes in
retinal thickness and visual acuity in treated patients (Larsson
et al., 2005). The visual signiﬁcance of OCT-derived parame-
ters other than retinal thickness/volume has also been assessed.
Alasil et al. demonstrated a signiﬁcant correlation between
visual acuity and photoreceptor outer segment thickening
and volume, but no association of vision with subretinal ﬂuid
volume (Alasil et al., 2010).
5.2. Retinal vein occlusion
Both central retinal vein occlusion (CRVO) and branch retinal
vein occlusion (BRVO) are common causes of macular edema
(Johnson, 2009). In these disorders, acute extravasation of
ﬂuid into the extracellular space of the retina results from in-
creased hydrostatic pressure in retinal veins distal to their
point of occlusion. In addition, growth factors released in re-
sponse to hypoxia may lead to breakdown of the inner
blood–retinal barrier, increasing ﬂuid extravasation. Macular
edema in retinal vein occlusion appears similar to that in
DME, although in BRVO the observed changes on OCT are
usually restricted to either the superior or inferior aspects of
the macula (Spaide et al., 2003). In addition, serous detach-
ment of the retina is more commonly seen in retinal vein occlu-
sions than from other etiologies, although the presence of
serous macular detachments does not appear to be associated
with worse visual outcomes (Catier et al., 2005). A number of
studies have evaluated the correlation between OCT-derived
retinal thickness parameters and visual acuity, but have only
identiﬁed moderate correlations (Scott et al., 2009). More re-
cently, studies have shown that the integrity of the ELM,
and photoreceptor IS–OS junction, appears to correlate with
visual acuity in both forms of retinal vein occlusion (Ota
et al., 2007, 2008a,b, 2010b; Yamaike et al., 2008).
5.3. Uveitic syndromes
Macular edema typically develops in patients with intermedi-
ate and posterior uveitis, but may also be seen in cases of
isolated anterior uveitis, and is a common cause of visual loss
(Gallagher et al., 2007; Tran et al., 2008; Iannetti et al., 2008).
Many of the edematous changes seen on OCT in DME may
also be seen in chronic uveitis and similar OCT–visual acuity
correlations have typically been described (Tran et al., 2008;
Roesel et al., 2009).
6. Central serous chorioretinopathy
Central serous chorioretinopathy (CSC) is a common macular
disorder characterized by serous detachment of the neurosen-sory retina and/or the RPE (Wang et al., 2008). CSC occurs
most commonly in young and middle-aged males and is often
only associated with modest reduction in visual function. CSC
is believed to occur as a result of choroidal hyperpermeability,
although the integrity of the RPE may play a role in determin-
ing the exact disease phenotype (Spitznas, 1986). On ﬂuores-
cein angiography in CSC, leakage of dye may be seen at the
level of the RPE, followed by pooling of the dye in the sub-
RPE and/or subretinal space. In some patients with CSC, par-
ticularly Asians and older age groups, multiple sites of pro-
longed or recurrent leakage may affect one or both eyes
leading to widespread abnormalities of the RPE – a condition
termed ‘‘chronic CSC’’ (Iida et al., 2003).
On OCT, the characteristic feature of CSC is the presence of
subretinal ﬂuid distributed in a disciform pattern (i.e. serous ret-
inal detachment), accompanied by one or more discrete areas of
PED (Iida et al., 2000; Montero and Ruiz-Moreno, 2005). Typ-
ically, the subretinal ﬂuid is homogeneously hyporeﬂective,
reﬂecting its serous nature, although subretinal ﬁbrinous depos-
its are sometimes present (Wang et al., 2005). In CSC, PEDs are
usually small, well demarcated, and lack any evidence of the
RPE hypertrophy or hyperplasia that can occur in PEDs
associated with other macular disorders (Cho et al., 2010; Ooto
et al., 2010). PEDs in CSC are also usually dome-shaped and
homogenously hyporeﬂective, with clear visibility of the Bruch
membrane/choriocapillaris complex. In Asian populations,
multiple larger PEDs are often seen and, in some cases, focal de-
fects in the RPE, associated with overlying hyperreﬂective
ﬁbrinous exudation, may be evident (Fujimoto et al., 2008).
When such ﬁbrinous exudation is severe it may result in the for-
mation of ﬁbrinous bands that extend between the RPE and the
neurosensory retina, and lead to sagging/dipping of the retina
over leakage sites in areas of serous detachment.
When patients with CSC are examined using OCT, changes
in the overlying neurosensory retina can also be observed (Ah-
lers et al., 2009a). Hyperreﬂective deposits are often seen
adherent to the undersurface of the retina in areas of serous
detachment – these deposits may represent fragments of pho-
toreceptor outer segments that have been incompletely phago-
cytosed due to separation from the RPE. In most patients with
CSC, the ELM appears intact on OCT, but the IS–OS junction
and outer plexiform layers show diffusely increased hyperre-
ﬂectivity (Ahlers et al., 2009a; Matsumoto et al., 2008). These
changes may represent structural changes in the neurosensory
retina, although recent studies suggest that they more likely re-
ﬂect changes in the OCT signal from changes in the orientation
of vertically oriented retinal microstructures (see above) (Lu-
jan et al., 2010; Otani et al., 2010). More recently, ‘‘enhanced
depth imaging’’ OCT has been used to evaluate choroidal
thickness in patients with CSC – these studies have demon-
strated that the choroidal thickness is signiﬁcantly greater in
patients with CSC than in normal eyes, and that treatment
with photodynamic therapy leads to reductions in this param-
eter (Imamura et al., 2009; Maruko et al., 2010).
Considerable efforts have been made to predict visual out-
comes using OCT in patients with CSC – particularly as the dis-
ease affects a relatively young population, often with ‘‘type A’’
personalities, for whom duration of symptoms and ultimate
visual prognosis is a major concern (Yannuzzi, 1987). Matsum-
oto et al. have demonstrated that thickness of the outer nuclear
layer is positively correlated with visual acuity in patients with
resolved CSC; they also reported that eyes with thinner outer
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manifest discontinuities of their IS–OS junctions when exam-
ined with OCT (Matsumoto et al., 2009). The importance of
both IS–OS junction and ELM integrity has been conﬁrmed in
other reports, many of which have also detected a relationship
between initial foveal thickness and ﬁnal visual outcome (Ojima
et al., 2007; Piccolino et al., 2005; Aggio et al., 2010; Shinojima
et al., 2010). In the near future, advances inOCT technologywill
allow enhanced visualization of both choroidal and RPE struc-
ture; such advances may allow the clinician to better predict the
course of the disease, including time to symptom resolution and
the likelihood of recurrent or chronic disease (Keane and Sadda,
2010).7. Non-neovascular age-related macular degeneration
The clinical hallmark of AMD is the deposition of acellular,
polymorphous material, termed drusen, between the RPE
and Bruch membrane (Jager et al., 2008). In early AMD, dru-
sen are often accompanied by focal retinal pigmentary abnor-
malities; as AMD progresses, alterations in the RPE often
accumulate, resulting in the loss of large areas of RPE and out-
er retina, a phenomenon termed GA (Sunness et al., 2007).
With current commercial OCT systems, small and interme-
diate size drusen may be clearly seen as discrete areas of RPE
elevation with variable reﬂectivity, reﬂecting the variable com-
position of the underlying material (Gorczynska et al., 2009;
Khanifar et al., 2008). In larger drusen, or drusenoid PED,
greater elevation of the RPE may be seen, often dome-shaped,
with a hypo- or medium-reﬂective material separating the RPE
from the underlying Bruch membrane (Roquet et al., 2004;
Spaide and Curcio, 2010). Larger drusen may often become
conﬂuent, resulting in a large lateral dimension, but no single
broad-domed lesion. On OCT, drusen are often accompanied
by changes in the overlying neurosensory retina – these may
be seen as disruption of the IS–OS junction and ELM, as well
as signiﬁcant thinning of the outer nuclear layer (Schuman
et al., 2009). These ﬁndings are consistent with previous histo-
pathologic studies demonstrating photoreceptor loss in pa-
tients with drusen (Curcio et al., 1996).
In GA, conﬂuent areas of RPE atrophy are accompanied
by loss of the overlying photoreceptors and varying degrees
of choriocapillaris loss seen on ﬂuorescein angiography
(Gass, 1997; Sunness, 1999). On OCT, GA appears as areas
of sharply demarcated choroidal hyperreﬂectivity due to loss
of the overlying RPE (atrophy from causes other than AMD
– e.g. from conﬂuent laser photocoagulation – may have a
similar appearance) (Wolf-Schnurrbusch et al., 2008). Associ-
ated retinal atrophy is seen as thinning or loss of the outer
nuclear layer and the absence of ELM and IS–OS junctions
(Fleckenstein et al., 2008). On OCT, islands of preserved
outer retina may sometime be identiﬁed in areas of GA, as
can regressing drusenoid materials, seen as hyperreﬂective
plaques at the level of the RPE. GA may also be associated
with the presence of small cyst-like spaces in the inner nucle-
ar layer, in the absence of macular edema (Cohen et al.,
2010).
Assessment of visual prognosis in patients with GA is
dependent on knowledge of GA size, location, and rates
of progression (Sunness et al., 2007). For the latter, fun-
dus autoﬂuorescence ﬁndings in the junctional zone sur-rounding GA have proven useful in highlighting those
cases likely to progress rapidly (Holz et al., 2007). Evaluation
of the junctional zones around GA, using OCT, has shown that
the ELM and IS–OS junctions may be seen to taper off, and
the outer plexiform later can be seen to approach toward
Bruch membrane (suggesting that photoreceptor loss often ex-
tends beyond the margins of GA lesions) (Bearelly et al., 2009).
OCT studies have also demonstrated a variety of dynamic
changes in the junctional zone, including pigment migration
and alterations in drusen height (Fleckenstein et al., 2010).
GA assessment using OCT may thus provide insight into dis-
ease pathogenesis, but its potential beneﬁts for prediction of
visual outcomes remain to be determined (Schu¨tze et al.,
2010; Yehoshua et al., 2010a,b; Brar et al., 2009a; Lujan
et al., 2009).
8. Conclusion
Following its release in 2002, Stratus OCT (Carl Zeiss Meditec,
Dublin, CA) became the ﬁrst OCT system to become ubiquitous
among retina specialists worldwide and led to signiﬁcant ad-
vances in the diagnosis and management of disorders such as
diabetic retinopathy and neovascular AMD. More recently,
the next generation of commercial OCT systems – spectral do-
main OCT – has provided signiﬁcant increases in image acquisi-
tion speed, resolution, and sensitivity. While use of spectral
domain OCT technology has led to the identiﬁcation of many
new structural features of macular disease, much work remains
to correlate these ﬁndings with visual function and, thus, to pre-
dict visual outcomes. The rate of ongoing change in OCT hard-
ware is also rapid, with new commercial systems expected to
allow enhanced visualization of the choroid as well direct,
non-invasive measurements of macular blood ﬂow, and greatly
increased speeds. Although our current ability to predict visual
outcomes using OCT remains somewhat limited, such advances
should ultimately allow clinicians a comprehensive understand-
ing of visual prognosis in macular disease, with all the attendant
beneﬁts for their patients.Disclosure
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